Laboratory of Influenza Research, College of Veterinary Medicine, Chungnam National University, Yuseong Gu, Daejeon, Republic of KoreaInterests: vaccine; epidemiology; pathogenicity on influenza virus and SARS-CoV-2Special Issues and Topics in IMR Press journalsSpecial Issue in Research on Influenza Viruses
Dear Colleagues，
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) known as covid-19 still causes tremendous burden on humans. This virus has many variants such as Alpha, Beta, Gamma and Delta. Some variants have the potential for the increased trasnsmissibility, increased virulence, or reduced effectiveness of vaccines against current vaccines.
We need to develop better vaccine for protecting people from being infected from emerging variants SARS-CoV2 and anti-viral drugs to treat humans infected with SARS-CoV2. The goal of this special issue is to publish new approach to vaccines and anti-viral drugs for SARS-CoV2. Interesting researchers are encouraged to submit short reports, and full papers based on animal studies and human clinical trials.
Prof. Sang Heui Seo
Guest Editor
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.
- Open Access Original ResearchComparison of the Pathogenicity of SARS-CoV-2 Delta and Omicron Variants by Analyzing the Expression Patterns of Immune Response Genes in K18-hACE2 Transgenic MiceKuruppu Arachchillage Praboda Priyangi Kuruppuarachchi, Yunyueng Jang, Sang Heui SeoFront. Biosci. (Landmark Ed) 2022, 27(11), 316; https://doi.org/10.31083/j.fbl2711316(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)138Downloads3Citations499Views
- Open Access ReviewAptamer-Mediated Antiviral Approaches for SARS-CoV-2Kei Xian Tan, Jaison Jeevanandam, João Rodrigues, Michael K. DanquahFront. Biosci. (Landmark Ed) 2022, 27(11), 306; https://doi.org/10.31083/j.fbl2711306(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)144Downloads2Citations385Views
- Open Access ReviewCombination Therapies against COVID-19Qunfeng Luo, Yunxi Zheng, Jin ZhangFront. Biosci. (Landmark Ed) 2022, 27(9), 257; https://doi.org/10.31083/j.fbl2709257(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)93Downloads280Views
- Open Access Original ResearchGinseng Protects ACE2-Transgenic Mice from SARS-CoV-2 InfectionSang Heui SeoFront. Biosci. (Landmark Ed) 2022, 27(6), 180; https://doi.org/10.31083/j.fbl2706180(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)81Downloads2Citations384Views
- Open Access ReviewThe Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19Jie Wang, Qian Zhang, Hongmei Wang, Wenping GongFront. Biosci. (Landmark Ed) 2022, 27(5), 157; https://doi.org/10.31083/j.fbl2705157(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)135Downloads9Citations568Views
- Open Access Original ResearchPotential SARS-CoV-2 nonstructural proteins inhibitors: drugs repurposing with drug-target networks and deep learningShayan K. Azmoodeh, Igor F. Tsigelny, Valentina L. KouznetsovaFront. Biosci. (Landmark Ed) 2022, 27(4), 113; https://doi.org/10.31083/j.fbl2704113(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)105Downloads2Citations537Views
- Open Access ReviewVariants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivityBirgit M. PrüβFront. Biosci. (Landmark Ed) 2022, 27(2), 65; https://doi.org/10.31083/j.fbl2702065(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)443Downloads12Citations1172Views
- Open Access Original ResearchThymosin-α1 binds with ACE and downregulates the expression of ACE2 in human respiratory epitheliaYu-Hang Zhang, Wen-Yu Wang, Xiao-Cong Pang, Zhi Wang, ... Yi-Min CuiFront. Biosci. (Landmark Ed) 2022, 27(2), 48; https://doi.org/10.31083/j.fbl2702048(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)107Downloads2Citations293Views
- Open Access Original ResearchUV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell linesEvelyn J. Franco, Kelly L. Warfield, Ashley N. BrownFront. Biosci. (Landmark Ed) 2022, 27(1), 3; https://doi.org/10.31083/j.fbl2701003(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)92Downloads4Citations383Views
- Open Access Original ResearchHeterogeneity in susceptibility to hydroxychloroquine of SARS-CoV-2 isolatesCeline Boschi, Marion Le Bideau, Julien Andreani, Sarah Aherfi, ... Bernard La ScolaFront. Biosci. (Landmark Ed) 2021, 26(12), 1493–1502; https://doi.org/10.52586/5043(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)68Downloads2Citations307Views